Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$311.55 +1.5%	$301.08	$253.30 ▼ $346.85	$167.37B	0.53	2.70 million shs	3.34 million shs
BMY Bristol-Myers Squibb	$61.05 +1.7%	$58.55	$39.35 ▼ $63.33	$123.89B	0.43	12.74 million shs	11.61 million shs
MRK Merck & Co., Inc.	$89.74 +0.6%	$91.92	$81.04 ▼ $134.63	$226.69B	0.35	11.07 million shs	15.00 million shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	0.00%	-2.88%	-0.36%	+18.38%	+7.96%
BMY Bristol-Myers Squibb	0.00%	-1.58%	+0.65%	+7.20%	+10.82%
MRK Merck & Co., Inc.	0.00%	-4.56%	-3.31%	-9.34%	-32.41%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMGN Amgen	4.4201 of 5 stars	2.2	4.0	3.3	3.9	3.6	2.5	0.6
BMY Bristol-Myers Squibb	3.8753 of 5 stars	1.2	3.0	4.2	4.0	3.6	3.3	0.0
MRK Merck & Co., Inc.	5 of 5 stars	4.3	5.0	5.0	3.9	2.2	3.3	3.8

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMGN Amgen	2.48	Hold	$314.04	0.80% Upside
BMY Bristol-Myers Squibb	2.32	Hold	$57.86	-5.23% Downside
MRK Merck & Co., Inc.	2.65	Moderate Buy	$117.12	30.50% Upside

Current Analyst Ratings Breakdown

Latest MRK, AMGN, and BMY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/5/2025	AMGN Amgen	Johnson Rice Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$294.00
3/5/2025	AMGN Amgen	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Underperform ➝ Underperform	$275.00 ➝ $294.00
2/18/2025	MRK Merck & Co., Inc.	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$128.00 ➝ $105.00
2/12/2025	AMGN Amgen	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
2/12/2025	MRK Merck & Co., Inc.	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$122.00 ➝ $115.00
2/10/2025	AMGN Amgen	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$310.00 ➝ $329.00
2/10/2025	MRK Merck & Co., Inc.	TD Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$121.00 ➝ $100.00
2/10/2025	MRK Merck & Co., Inc.	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$121.00 ➝ $100.00
2/7/2025	BMY Bristol-Myers Squibb	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$60.00 ➝ $62.00
2/6/2025	AMGN Amgen	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Underperform ➝ Underperform	$256.00 ➝ $275.00
2/5/2025	AMGN Amgen	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight ➝ Equal Weight

(Data available from 3/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMGN Amgen	$33.42B	5.01	$31.22 per share	9.98	$10.93 per share	28.50
BMY Bristol-Myers Squibb	$48.30B	2.56	$6.44 per share	9.48	$8.08 per share	7.56
MRK Merck & Co., Inc.	$64.17B	3.53	$3.11 per share	28.82	$14.85 per share	6.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMGN Amgen	$4.09B	$7.55	41.26	14.57	2.63	12.24%	176.32%	11.71%	5/1/2025 (Estimated)
BMY Bristol-Myers Squibb	-$8.95B	-$4.42	N/A	10.02	2.07	-18.53%	13.93%	2.46%	4/24/2025 (Estimated)
MRK Merck & Co., Inc.	$17.12B	$6.73	13.33	9.06	0.77	26.67%	45.35%	17.36%	4/24/2025 (Estimated)

Latest MRK, AMGN, and BMY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/24/2025	N/A	BMY Bristol-Myers Squibb	$1.55	N/A	N/A	N/A	$10.77 billion	N/A
4/24/2025	N/A	MRK Merck & Co., Inc.	$2.16	N/A	N/A	N/A	$15.59 billion	N/A
2/6/2025	Q4 2024	BMY Bristol-Myers Squibb	$1.47	$1.67	+$0.20	$0.04	$11.57 billion	N/A
2/4/2025	Q4 2024	AMGN Amgen	$5.04	$5.31	+$0.27	$1.16	$8.87 billion	N/A
2/4/2025	Q4 2024	MRK Merck & Co., Inc.	$1.85	$1.72	-$0.13	$1.48	$15.51 billion	$15.62 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMGN Amgen	$9.52	3.06%	+8.53%	126.09%	14 Years
BMY Bristol-Myers Squibb	$2.48	4.06%	+6.38%	N/A	17 Years
MRK Merck & Co., Inc.	$3.24	3.61%	+5.73%	48.14%	14 Years

Latest MRK, AMGN, and BMY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
3/4/2025	AMGN Amgen	quarterly	$2.38	3.05%	5/16/2025	5/16/2025	6/6/2025
3/3/2025	BMY Bristol-Myers Squibb	quarterly	$0.62	4.14%	4/4/2025	4/4/2025	5/1/2025
1/28/2025	MRK Merck & Co., Inc.	quarterly	$0.81	3.32%	3/17/2025	3/17/2025	4/7/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMGN Amgen	9.62	1.26	0.95
BMY Bristol-Myers Squibb	2.90	1.25	1.15
MRK Merck & Co., Inc.	0.79	1.36	1.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMGN Amgen	76.50%
BMY Bristol-Myers Squibb	76.41%
MRK Merck & Co., Inc.	76.07%

Insider Ownership

Company	Insider Ownership
AMGN Amgen	0.69%
BMY Bristol-Myers Squibb	0.09%
MRK Merck & Co., Inc.	0.09%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMGN Amgen	28,000	537.21 million	533.50 million	Optionable
BMY Bristol-Myers Squibb	34,300	2.03 billion	2.03 billion	Optionable
MRK Merck & Co., Inc.	69,000	2.53 billion	2.53 billion	Optionable

MRK, AMGN, and BMY Headlines

Recent News About These Companies

Contact Levi & Korsinsky by April 14, 2025 Deadline to Join Class Action Against Merck & Co., Inc.(MRK)

March 31 at 6:30 PM | accessnewswire.com

ROSEN, A RANKED AND LEADING FIRM, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK

March 31 at 6:00 PM | accessnewswire.com

Merck & Co., Inc. (NYSE:MRK) Stock Price Down 0.1% - Time to Sell?

March 31 at 2:45 PM | marketbeat.com

Levi & Korsinsky Notifies Merck & Co., Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MRK

March 31 at 2:30 PM | accessnewswire.com

Merck & Co., Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before April 14, 2025 to Discuss Your Rights – MRK

March 31 at 1:13 PM | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines - MRK

March 31 at 12:43 PM | prnewswire.com

Shareholders that lost money on Merck & Co., Inc.(MRK) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

March 31 at 12:30 PM | accessnewswire.com

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Merck Lawsuit - MRK

March 31 at 7:25 AM | accessnewswire.com

Merck & Co., Inc. (NYSE:MRK) Shares Sold by HighPoint Advisor Group LLC

March 31 at 7:19 AM | marketbeat.com

Merck & Co., Inc. (NYSE:MRK) Shares Purchased by Franklin Resources Inc.

March 31 at 7:09 AM | marketbeat.com

MRK SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Investors Have Opportunity to Lead Class Action Lawsuit!

March 31 at 7:00 AM | accessnewswire.com

B. Metzler seel. Sohn & Co. AG Grows Position in Merck & Co., Inc. (NYSE:MRK)

March 31 at 6:57 AM | marketbeat.com

Rodgers Brothers Inc. Grows Stock Holdings in Merck & Co., Inc. (NYSE:MRK)

March 31 at 6:56 AM | marketbeat.com

Summit Financial LLC Increases Stock Holdings in Merck & Co., Inc. (NYSE:MRK)

March 31 at 6:39 AM | marketbeat.com

Merck & Co., Inc. (NYSE:MRK) Shares Sold by Alliancebernstein L.P.

March 31 at 6:38 AM | marketbeat.com

Lost Money on Merck & Co., Inc.(MRK)? Join Class Action Suit Seeking Recovery - Contact The ...

March 31 at 6:32 AM | gurufocus.com

St. James Investment Company LLC Has $9.72 Million Stake in Merck & Co., Inc. (NYSE:MRK)

March 31 at 6:14 AM | marketbeat.com

AIA Group Ltd Buys 200,498 Shares of Merck & Co., Inc. (NYSE:MRK)

March 31 at 6:00 AM | marketbeat.com

Wellington Management Group LLP Grows Stock Position in Merck & Co., Inc. (NYSE:MRK)

March 31 at 5:52 AM | marketbeat.com

Merck & Co., Inc. (NYSE:MRK) Holdings Reduced by Skba Capital Management LLC

March 31 at 5:52 AM | marketbeat.com

Lost Money on Merck & Co., Inc.(MRK)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm

March 31 at 5:45 AM | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRK, AMGN, and BMY Company Descriptions

Amgen NASDAQ:AMGN

$311.55 +4.60 (+1.50%)

Closing price 04:00 PM Eastern

Extended Trading

$307.60 -3.95 (-1.27%)

As of 06:44 PM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Bristol-Myers Squibb NYSE:BMY

$61.05 +1.03 (+1.72%)

Closing price 03:59 PM Eastern

Extended Trading

$60.95 -0.10 (-0.16%)

As of 06:35 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Merck & Co., Inc. NYSE:MRK

$89.74 +0.51 (+0.57%)

Closing price 03:59 PM Eastern

Extended Trading

$89.32 -0.42 (-0.47%)

As of 06:40 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time